Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Investigation whether a switch from oral iron to intravenous ferric carboxymaltose can reduce
dose requirements of erythropoiesis-stimulating agents (ESA) and improve Hb levels and iron
status in adult patients with non-dialysis-dependent CKD who were on a stable ESA/oral iron
schedule for 6 months prior to enrolment.